News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xcyte Therapies, Inc. Announces Full-Year And Fourth-Quarter 2004 Financial Results


10/19/2005 5:13:11 PM

SEATTLE--(BUSINESS WIRE)--March 31, 2005--Xcyte Therapies, Inc. (Xcyte, the "Company") (Nasdaq:XCYT) reported today a net loss applicable to common shareholders of $48.6 million, or $3.90 per basic and diluted share, for the year ended December 31, 2004, compared with $18.5 million, or $12.40 per basic and diluted share, for the year ended December 31, 2003. Revenue during 2004 totaled $62,000, compared with $170,000 during 2003. Total operating expenses were $26.6 million for the year ended December 31, 2004, compared with $18.0 million for the year-earlier period. Research and development expenses were $19.7 million and $13.7 million in 2004 and 2003, respectively, while general and administrative expenses were $6.9 million and $4.3 million in the same periods.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES